China Cord Blood Corp. (NYSE:CO)

CAPS Rating: 1 out of 5

The company operates as a cord blood bank in China, providing laboratory testing, cord blood collection, stem cell storage services, and hematopoietic stem cell processing.

Results 1 - 7 of 7

Recs

0
Member Avatar sfinx (< 20) Submitted: 5/10/2014 10:58:26 PM : Outperform Start Price: $4.52 CO Score: -2.81

Backing from the Chinese government for such a firm/brand to prosper on the market in my humble opinion and high demand in the region(China).

Recs

0
Member Avatar AnsgarJohn (99.17) Submitted: 5/31/2013 7:00:26 AM : Underperform Start Price: $2.78 CO Score: -46.42

China reverse merger , fraud?

Recs

0
Member Avatar Volke (81.67) Submitted: 11/6/2012 10:48:07 PM : Underperform Start Price: $2.90 CO Score: -19.43

Not exactly a booming industry, and no one has even heard of it. It's currently lower than it's IPO price, and that was years ago.

Recs

1
Member Avatar Allstar13913 (99.80) Submitted: 7/30/2011 7:50:54 PM : Underperform Start Price: $2.70 CO Score: -35.08

China reverse merger that seems to be diluting shareholder value at the expense of insiders.

Recs

1
Member Avatar ChinaRTO (99.89) Submitted: 4/14/2011 3:27:53 AM : Underperform Start Price: $3.35 CO Score: +13.78

This is a tracking portfolio of all CAPS-ratable tickers in the Chinese RTO/SPAC space (i.e., companies that listed without filing an IPO).

China Cord Blood Corp. went public via a blank check (SPAC) merger in 2009. The company is based in China.

Recs

0
Member Avatar freepatent (< 20) Submitted: 1/3/2011 11:07:26 AM : Outperform Start Price: $3.94 CO Score: -38.45

CO is better than NKBP, NKBP is a chinese flop

Recs

0
Member Avatar franktejon (< 20) Submitted: 11/6/2010 4:16:26 PM : Outperform Start Price: $4.15 CO Score: -50.81

strong buy

Results 1 - 7 of 7

Featured Broker Partners


Advertisement